 "Dr Reddy's completes acquisition of product portfolio from Teva")
Dr Reddy’s Laboratories Ltd has forayed into Colombia with its portfolio of high quality and affordable medicines for cancer patients.
“Our company has a track record of staying committed to the markets we serve. We are delighted to make a beginning towards serving the unmet needs of patients in Colombia. Our initial focus would be to provide access to affordable cancer medicines to patients through our proven portfolio of oncology products,” said M V Ramana, executive vice president and head, branded markets, global generics of Dr Reddy’s Laboratories.
Dr Reddy’s, one of the leading generic oncology companies in India, is the second largest generic oncology injectable company by value in the US, according to IMS Health 2015. Over the years, the company has been expanding its international business and is currently present in 26 countries.
Dr Reddy’s operates in all major regions across the world with the major markets being - USA, India, Russia & CIS countries, and Europe with a workforce of over 20000 employees. The company’s more than 20 manufacturing facilities are supported by five technology development centres, two integrated product development centres and three research & development (R&D) centres.
Through its three businesses - pharmaceutical services & active ingredients, global generics and proprietary products - Dr Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Considered to be one of the global leaders in the generic industry, Dr Reddy’s focuses on making generic and complex products across the major therapeutic areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
